RxDoctor Payments Data

Trevor Payne

Foot & Ankle Surgery · Augusta, GANPI 1467887877

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,927 of the $6,592 with a category attached, or 74.7%. It is spread thinly across 42 manufacturers, the largest accounting for just 20.3%. 2025 is the largest year on record at $1,751, 3.3 times the $537 reported in 2019.

$6,592in general payments, 2019–2025

Across 166 payments — averaging $39.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Convatec Inc.$1K
  • Treace Medical Concepts, Inc.$1K
  • Stryker$770
  • Smith+Nephew$432
  • Amgen$359
  • Johnson & Johnson$298
  • plus $2K from 36 others

What the payments were for

  • Consulting fees$1002%
  • Travel & lodging$3656%
  • Food & beverage$4,92775%
  • Other$1,20018%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,592 in reported general payments places this provider in the 75th percentile of 239 foot & ankle surgery providers in Georgia.

See all foot & ankle surgery providers in Georgia

Medicare billing

Part B allowed, 2024
$216,270
Medicare patients
450
Services billed
2,799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban12$7,706
SantylCollagenase Clostridium Hist.14$6,598
Ammonium Lactate200$4,681
Ketoconazole66$1,515
Ciclopirox28$491
Mupirocin59$365
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav36$307
Doxycycline Hyclate32$293
Clindamycin Hcl37$267
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen29$193
Gabapentin20$120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$298$7,70612 claims
Smith+NephewSantyl$432$6,59814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 239 foot & ankle surgery providers in Georgia.

Other foot & ankle surgery in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →